Blocking the JAK2/STAT3 signaling pathway in non-small cell carcinoma (NSCLC) inhibits the proliferation, angiogenesis, invasion, and migration ability of NSCLC and additionally inhibits the development of lung cancer (26, 27). This evidence concerns the gene JAK2 and lung cancer.